Search research articles
Contact Us
Filters
Showing results (501-510 of 543) with videos related to
Page
of 55
Sort By:
Human Pathology
|
October 13, 2014
The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma
Sandra Steffens, Martin Janssen, Frederik C Roos, et al.
The Lancet. Neurology
|
December 6, 2011
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Sarah J Tabrizi, Ralf Reilmann, Raymund A C Roos, et al.
Ebiomedicine
|
October 15, 2019
A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes
Marc Ciosi, Alastair Maxwell, Sarah A Cumming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2006
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients
Pontus K E Börjesson, Yvonne W S Jauw, Ronald Boellaard, et al.
Cancer Immunology, Immunotherapy : CII
|
October 2, 1998
Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01
H M Prinssen, C F Molthoff, R H Verheijen, et al.
British Journal of Clinical Pharmacology
|
November 16, 2020
Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part study
Marcus P J van Diemen, Ellen P Hart, Anthony Abbruscato, et al.
JAMA Neurology
|
August 13, 2019
Association of CAG Repeats With Long-term Progression in Huntington Disease
Douglas R Langbehn, Julie C Stout, Sarah Gregory, et al.
BJOG : an International Journal of Obstetrics and Gynaecology
|
March 4, 2020
Effects of tocolysis with nifedipine or atosiban on child outcome: follow-up of the APOSTEL III trial
Tms van Winden, J Klumper, C E Kleinrouweler, et al.
Neurobiology of Aging
|
October 14, 2018
Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease
Sarah L Gardiner, Aster V E Harder, Yvonne J M Campman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
February 12, 2015
Short-interval observational data to inform clinical trial design in Huntington's disease
Nicola Z Hobbs, Ruth E Farmer, Elin M Rees, et al.
Page
of 55
Search research articles
Search
Showing results (501-510 of 543) with videos related to
Sort By:
Page
of 55
Human Pathology
|
October 13, 2014
The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma
Sandra Steffens, Martin Janssen, Frederik C Roos, et al.
The Lancet. Neurology
|
December 6, 2011
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Sarah J Tabrizi, Ralf Reilmann, Raymund A C Roos, et al.
Ebiomedicine
|
October 15, 2019
A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes
Marc Ciosi, Alastair Maxwell, Sarah A Cumming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2006
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients
Pontus K E Börjesson, Yvonne W S Jauw, Ronald Boellaard, et al.
Cancer Immunology, Immunotherapy : CII
|
October 2, 1998
Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01
H M Prinssen, C F Molthoff, R H Verheijen, et al.
British Journal of Clinical Pharmacology
|
November 16, 2020
Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part study
Marcus P J van Diemen, Ellen P Hart, Anthony Abbruscato, et al.
JAMA Neurology
|
August 13, 2019
Association of CAG Repeats With Long-term Progression in Huntington Disease
Douglas R Langbehn, Julie C Stout, Sarah Gregory, et al.
BJOG : an International Journal of Obstetrics and Gynaecology
|
March 4, 2020
Effects of tocolysis with nifedipine or atosiban on child outcome: follow-up of the APOSTEL III trial
Tms van Winden, J Klumper, C E Kleinrouweler, et al.
Neurobiology of Aging
|
October 14, 2018
Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease
Sarah L Gardiner, Aster V E Harder, Yvonne J M Campman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
February 12, 2015
Short-interval observational data to inform clinical trial design in Huntington's disease
Nicola Z Hobbs, Ruth E Farmer, Elin M Rees, et al.
Page
of 55